Chemclin is a leading Chinese diagnostic business for infectious disease and oncology tests. The company provides in vitro diagnostics (“IVD”) and Chemiluminescence Immunoassay (“CLIA”) tests enabling hospitals to offer disease screening, diagnosis and biochemical technology.
China’s IVD sector is the fourth largest globally. Over the past 20 years China has experienced a rapid social and economic transformation. Changing consumer preferences, increasingly heath conscious lifestyles and rising incomes have contributed to an ageing population, increasing demand for more and improved healthcare options.
In 2013, Actis led a consortium with CICC Private Equity and OrbiMed, to acquire a majority stake in Chemclin. A year later, as part of the platform strategy for Chemclin, Actis worked with management to originate, finance and to acquire a controlling stake in Beyond Diagnostics, a local IVD company with proprietary and world-leading complimentary CLIA technology and a product portfolio targeting new consumer segments.
Alongside management Actis helped to develop Chemclin’s business strategy and incentive plan. Over the last five years, Chemclin has expanded its hospital network and maintained its leadership position in a highly competitive market.
In 2018 Actis announced its successful exit for US$150 million.